Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameGuanze Medical
Stock Code02427
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家立足於山東省的醫學影像解決方案供應商,主要從事提供醫用影像膠片產品及醫學影像雲服務。
Listing Date2022-12-29
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)山東省濟南市高新區春暉路2966號濟南高新區戰略性新興產業基地10座501-A室
Business Address (Hong Kong)德輔道西246號東慈商業中心8樓02室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteguanzegroup.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 0.53 / shares
Offer Price RangeFinal offer price only, no range
Lot Size5,000 shares
Entry ThresholdHK$ 2,650
Par ValueTo be extracted
Offer Period2022-12-15 to 2022-12-20
Global Offering Shares192,850,000 shares
HK Public Offer Shares (Initial)19,285,000 shares (10.0%)
Public Offer Lots (Initial)3,857lots (Pool A1,928lots,Pool B1,929lots)
International Placing Shares (Initial)173,565,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO950,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share29.2%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 102,210,500

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 5,000 HK$ 2,650
2 lots 10,000 HK$ 5,300
3 lots 15,000 HK$ 7,950
4 lots 20,000 HK$ 10,600
5 lots 25,000 HK$ 13,250
6 lots 30,000 HK$ 15,900
7 lots 35,000 HK$ 18,550
8 lots 40,000 HK$ 21,200
9 lots 45,000 HK$ 23,850
10 lots 50,000 HK$ 26,500
12 lots 60,000 HK$ 31,800
14 lots 70,000 HK$ 37,100
16 lots 80,000 HK$ 42,400
18 lots 90,000 HK$ 47,700
20 lots 100,000 HK$ 53,000
30 lots 150,000 HK$ 79,500
40 lots 200,000 HK$ 106,000
50 lots 250,000 HK$ 132,500
60 lots 300,000 HK$ 159,000
70 lots 350,000 HK$ 185,500
80 lots 400,000 HK$ 212,000
90 lots 450,000 HK$ 238,500
100 lots 500,000 HK$ 265,000
120 lots 600,000 HK$ 318,000
140 lots 700,000 HK$ 371,000
160 lots 800,000 HK$ 424,000
180 lots 900,000 HK$ 477,000
200 lots 1,000,000 HK$ 530,000
300 lots 1,500,000 HK$ 795,000
400 lots 2,000,000 HK$ 1,060,000
700 lots 3,500,000 HK$ 1,855,000
800 lots 4,000,000 HK$ 2,120,000
1,400 lots 7,000,000 HK$ 3,710,000
1,600 lots 8,000,000 HK$ 4,240,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 2.72B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +258%

Valuation & Financials

Market Cap (at Offer Price)HK$ 503,500,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣23.1百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 202020212022
Revenue 184,435106,72898,621
Cost of sales -122,860-70,340-58,995
Gross profit 61,57536,38839,626
Other income and gains, net 7451,2831,640
Selling and distribution expenses -16,957-11,624-12,253
Administrative expenses -3,878-9,246-6,552
Profit before tax 39,00316,03321,494
Income tax expense -9,960-4,866-6,092
Profit for the year 29,04311,16715,402
Profit attributable to owners 29,04311,09515,316
Balance Sheet
Item 2019202020212022-062022
Cash and cash equivalents 5,52120,23514,925
Trade and bills receivables 96,630137,249166,861
Inventories 21,63212,5713,428
Total current assets 125,867173,488199,554
Total assets 153,885204,051232,047
Total current liabilities 51,63341,33753,955
Total liabilities 55,44541,49154,085
Total equity 98,440162,560177,962
Equity attributable to owners 98,440162,397177,713
Interest-bearing borrowings 1,0008,31315,0001,509
Cash Flow Statement
Item 2019202020212022-062022
Net cash from operating activities 28,1684,579-2,278
Net cash from investing activities -9,831-7,856-4,168
Net cash from financing activities -19,31017,9911,136
Net increase in cash -97314,714-5,310
Depreciation of PP&E 1,1192,2083,2751,990
Depreciation of right-of-use assets 133255310155
Amortisation of intangible assets 816824833418
Purchase of PP&E -7,490-7,811-11,541-45
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 1.75
First Day OpenHK$ 1.2
First Day Change230.19%
First Day Volume63010000.0
First Day Turnover92718800.0
Use of Proceeds
1、約34.0百萬港元(約46.4%)將用于延伸至山東省東部,以擴闊客戶基礎及進一步鞏固于山東省的市場地位; 2、約27.4百萬港元(約37.3%)將用于藉由策略性收購、取得醫療器械注冊證及將軟硬件升級以加強醫學影像云服務的供應; 3、約2.0百萬港元(約2.7%)將用于擴大產品組合以橫向擴充價值鏈; 4、約1.8百萬港元(約2.5%)將用于藉由參與交易會、貿易展覽及會議,不斷推廣我們的品牌及增加市場知名度; 5、約1.8百萬港元(約2.5%)將用于我們的信息科技系統升級; 6、約6.3百萬港元(約8.6%)將用作額外營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
Southwest Securities (HK) Capital Limited CE AIC042
Overall Coordinators (3)
SOUTHWEST SECURITIES (HK) BROKERAGE LIMITED CE ACB501 GOLDLINK SECURITIES LIMITED CE BHH779 Funde Securities Limited CE BHT984
Joint Bookrunners (10)
SOUTHWEST SECURITIES (HK) BROKERAGE LIMITED CE ACB501 GOLDLINK SECURITIES LIMITED CE BHH779 Funde Securities Limited CE BHT984 交银国际证券有限公司 CE APJ121 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 SPDB International Capital Limited CE BFZ375 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 Alpha Financial Group Limited CE ALW542 Apricot Capital (Hong Kong) Limited CE ACX624
Joint Lead Managers (11)
SOUTHWEST SECURITIES (HK) BROKERAGE LIMITED CE ACB501 GOLDLINK SECURITIES LIMITED CE BHH779 Funde Securities Limited CE BHT984 交银国际证券有限公司 CE APJ121 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 SPDB International Capital Limited CE BFZ375 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 Alpha Financial Group Limited CE ALW542 Apricot Capital (Hong Kong) Limited CE ACX624 I WIN SECURITIES LIMITED CE BJB315

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Carsonlin Investment Ltd 22,111,600 HKD — 21.60% — 6 months 2023-06-29
2 慕敏 2,210,100 HKD — 2.20% — 6 months 2023-06-29
3 杨新云 5,527,900 HKD — 5.40% — 6 months 2023-06-29

Directors & Management

PositionChinese nameEnglish Name
Chairman孟憲震—
Company Secretary張森泉—
No director data available.

Major Shareholders

Major Shareholders & HoldingsMeng A Capital、孟憲震先生及楊段玲女士於緊隨資本化發行及全球發售完成後分別持有本公司已發行股本約74.96%(假設超額配股權未獲行使)。
About this page

This page shows Guanze Medical (02427) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect